Brief: Interpace Announces Acceptance Of Seminal Clinical Validation Study For Thyroid Assays
21/07/2020 11:23
Interpace Biosciences Inc IDXG.O :
* INTERPACE ANNOUNCES ACCEPTANCE OF SEMINAL CLINICAL
VALIDATION
STUDY FOR THYROID ASSAYS
Source text for Eikon: ID:nGNX8Z7kdf
Further company coverage: IDXG.O
Recent news on Interpace Biosciences
See all newsBrief: Interpace Biosciences Announces Reverse Stock Split To Support Proposed Nasdaq Uplisting
Interpace Biosciences Q2 revenue falls despite growth in thyroid business
Brief: Interpace Biosciences Q2 Revenue USD 9.131 Million
Interpace Biosciences Q1 revenue falls
Brief: Interpace Biosciences Q1 Revenue USD 9.032 Million